DE69122777D1 - Zielgerichtete spezifische antikörper-superantigen konjugate und ihre präparation - Google Patents

Zielgerichtete spezifische antikörper-superantigen konjugate und ihre präparation

Info

Publication number
DE69122777D1
DE69122777D1 DE69122777T DE69122777T DE69122777D1 DE 69122777 D1 DE69122777 D1 DE 69122777D1 DE 69122777 T DE69122777 T DE 69122777T DE 69122777 T DE69122777 T DE 69122777T DE 69122777 D1 DE69122777 D1 DE 69122777D1
Authority
DE
Germany
Prior art keywords
conjugate
cells
superantigous
conjugates
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69122777T
Other languages
English (en)
Other versions
DE69122777T2 (de
Inventor
Terje Kalland
Gunnar Hedlund
Mikael Dohlsten
Peter Lando
Eva Akerblom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9002479A external-priority patent/SE9002479D0/xx
Priority claimed from SE9002484A external-priority patent/SE9002484L/xx
Application filed by Pharmacia AB filed Critical Pharmacia AB
Publication of DE69122777D1 publication Critical patent/DE69122777D1/de
Application granted granted Critical
Publication of DE69122777T2 publication Critical patent/DE69122777T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE69122777T 1990-07-20 1991-07-16 Zielgerichtete spezifische antikörper-superantigen konjugate und ihre präparation Expired - Lifetime DE69122777T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9002479A SE9002479D0 (sv) 1990-07-20 1990-07-20 Antibody conjugates
SE9002484A SE9002484L (sv) 1990-07-20 1990-07-20 Nya substituerade polyetrar
PCT/SE1991/000496 WO1992001470A1 (en) 1990-07-20 1991-07-16 Target specific antibody-superantigen conjugates and their preparation

Publications (2)

Publication Number Publication Date
DE69122777D1 true DE69122777D1 (de) 1996-11-21
DE69122777T2 DE69122777T2 (de) 1997-04-10

Family

ID=26660818

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69122777T Expired - Lifetime DE69122777T2 (de) 1990-07-20 1991-07-16 Zielgerichtete spezifische antikörper-superantigen konjugate und ihre präparation

Country Status (16)

Country Link
EP (1) EP0610179B1 (de)
JP (1) JP3334130B2 (de)
KR (1) KR100189024B1 (de)
AT (1) ATE144145T1 (de)
AU (1) AU656906B2 (de)
CA (1) CA2087164C (de)
DE (1) DE69122777T2 (de)
DK (1) DK0610179T3 (de)
ES (1) ES2094231T3 (de)
GR (1) GR3022202T3 (de)
HK (1) HK1007955A1 (de)
HU (1) HU218603B (de)
LV (1) LV10201B (de)
NO (1) NO312816B1 (de)
RU (1) RU2125889C1 (de)
WO (1) WO1992001470A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042837A (en) * 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
US5728388A (en) * 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6126945A (en) 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
US6197299B1 (en) 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
SE9102074D0 (sv) * 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
GB9114399D0 (en) * 1991-07-03 1991-08-21 Ici Plc Conjugates
CA2452130A1 (en) * 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
EP0659438A1 (de) * 1993-12-23 1995-06-28 Boehringer Mannheim Gmbh Konjugate, bestehend aus peptidischen T-Zell Antigenen und eine Zell-bindende Gruppe, und deren Verwendung in der Therapie
GB9326574D0 (en) * 1993-12-31 1994-03-02 King S College London Dry power inhalers
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
JP3871713B2 (ja) * 1995-05-10 2007-01-24 協和醗酵工業株式会社 新規毒素複合体
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
AU750414B2 (en) 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4797491A (en) * 1986-03-17 1989-01-10 Cetus Corporation Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane
US4806494A (en) * 1986-07-24 1989-02-21 The United States Of America As Represented By The Department Of Health & Human Services Monoclonal antibody against ovarian cancer cells (OVB-3)
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
US4981979A (en) * 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5004692A (en) * 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
IL89504A0 (en) * 1988-03-08 1989-09-10 Univ Wyoming Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same
EP0334300A1 (de) * 1988-03-21 1989-09-27 Neorx Corporation Verwendung von monoklonalen Antikörpern und deren Konjugaten als Leitgruppen zum Transport von sensibilisierten Effektorzellen an Tumorstellen
JPH02196799A (ja) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol 抗ヒト癌蛋白複合体

Also Published As

Publication number Publication date
NO312816B1 (no) 2002-07-08
NO930174L (no) 1993-01-19
HU9300148D0 (en) 1993-04-28
DE69122777T2 (de) 1997-04-10
NO930174D0 (no) 1993-01-19
AU656906B2 (en) 1995-02-23
HU218603B (hu) 2000-10-28
ES2094231T3 (es) 1997-01-16
JPH05508856A (ja) 1993-12-09
WO1992001470A1 (en) 1992-02-06
AU8294191A (en) 1992-02-18
GR3022202T3 (en) 1997-03-31
CA2087164A1 (en) 1992-01-21
JP3334130B2 (ja) 2002-10-15
EP0610179A1 (de) 1994-08-17
RU2125889C1 (ru) 1999-02-10
KR100189024B1 (ko) 1999-06-01
LV10201B (en) 1995-08-20
EP0610179B1 (de) 1996-10-16
DK0610179T3 (da) 1997-03-24
HK1007955A1 (en) 1999-04-30
HUT67502A (en) 1995-04-28
ATE144145T1 (de) 1996-11-15
LV10201A (lv) 1994-10-20
CA2087164C (en) 2002-11-26

Similar Documents

Publication Publication Date Title
DE69122777D1 (de) Zielgerichtete spezifische antikörper-superantigen konjugate und ihre präparation
OA07388A (fr) Nouveaux conjugués associant, par liaison convalente, une enzyme et un anticorps et associations médicamenteuses utilisant lesdits conjugués.
ES2118084T3 (es) Anticuerpos anti-icam-1 quimericos humanizados, metodos de preparacion y su uso.
DK0693132T3 (da) Rapamycinassay
CA2078118A1 (en) Cc-1065 analogs
EA200301159A1 (ru) Цитотоксические иммуноконъюгаты антитела к cd44
ATE320265T1 (de) Staphylococcus-antigene und impstoff
CA2434009A1 (en) Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
DE69333107T2 (de) Dualer träger für immunogene konstrukte
EA199901016A1 (ru) 9-оксим-производные эритромицина
RU93004918A (ru) Новые конъюгаты антитело-суперантиген, способ их получения, способ лизирования клетки-мишени, способ лечения и использование конъюгатов для получения фармкомпозиции
ATE137242T1 (de) Kovalente-ther lipidnukleosid-konjugate
FR2802536B1 (fr) Oligomannosides de synthese, leur preparation et leur utilisation a la detection d'anticorps et a la prevention d'infections
DK0491865T3 (da) Konjugatvaccine for gruppe B-Streptococcus
WO2005108430A3 (en) Monoclonal antibody sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
AU6628386A (en) Ricin-antibody conjugates
WO2002038611A3 (en) Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
WO2023141500A8 (en) Nanobody-drug adducts and uses thereof
EA200300725A1 (ru) Соединение азола в качестве противогрибковых средств
WO2024178360A3 (en) Auristatin analogs and antibody conjugates thereof
WO2024182318A3 (en) Antibodies to htra1 and conjugates thereof
CA2156397A1 (en) Rapamycin assay
TH13782EX (th) คู่สังยุคชนิดใหม่สำหรับการให้กรดนิวคลีอิคเข้าสู่เซลล์ยูคารีโอทชั้นสูง
TH11834EX (th) แอนติบอดีสังยุค

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: PHARMACIA & UPJOHN AB, STOCKHOLM, SE

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ACTIVE BIOTECH AB, LUND, SE